Academic radiology · 2020
Long-term Clinical Outcomes of US-Guided High-Intensity Focused Ultrasound Ablation for Symptomatic Submucosal Fibroids: A Retrospective Comparison with Uterus-Sparing Surgery.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yang, Liu Xin, Wang Wei, Tang Jie, Song Lei
Аннотация
RATIONALE AND OBJECTIVES: Uterus-sparing surgery and ultrasound (US)-guided high-intensity focused ultrasound (HIFU) ablation are both treatment options for symptomatic submucosal fibroids. No study had compared the long-term clinical outcomes between the two techniques. Therefore, the aim of this study was to compare the long-term clinical outcomes between US-guided HIFU ablation and uterus-sparing surgery for the treatment of symptomatic submucosal fibroids.
MATERIALS AND METHODS: A retrospective study was conducted on 245 women who were treated by US-guided HIFU ablation and 129 women who underwent uterus-sparing surgery for type I or type II symptomatic submucosal fibroids in a single institution from January 2007 to January 2015. The mean diameter of the fibroids was about 6 cm in both groups. They were followed up until December 2018. The symptom relief rate, symptom recurrence rate and incidence of major complications were compared between the two groups.
RESULTS: The symptom relief rate was 95.9% for US-guided HIFU ablation and 89.1% for uterus-sparing surgery. The cumulative symptom recurrence rate at 1-, 3-, 5-, and 8 years was 1.7%, 6.8%, 9.4%, and 11.9% for US-guided HIFU ablation and 6.1%, 12.2%, 22.6%, and 27.8% for uterus-sparing surgery. Compared to uterus-sparing surgery group, US-guided HIFU ablation had a statistically higher symptom relief rate and a lower symptom recurrence rate (p < 0.05). The major complication rate was 3.1% in the uterus-sparing surgery group. No major complications occurred in the US-guided HIFU ablation group.
CONCLUSION: This study showed that the long-term clinical outcomes of US-guided HIFU ablation may be better that of uterus-sparing surgery for the treatment of symptomatic submucosal fibroids. US-guided HIFU ablation may also be safer than uterus-sparing surgery. Further larger randomized trials are needed to confirm these findings.
MATERIALS AND METHODS: A retrospective study was conducted on 245 women who were treated by US-guided HIFU ablation and 129 women who underwent uterus-sparing surgery for type I or type II symptomatic submucosal fibroids in a single institution from January 2007 to January 2015. The mean diameter of the fibroids was about 6 cm in both groups. They were followed up until December 2018. The symptom relief rate, symptom recurrence rate and incidence of major complications were compared between the two groups.
RESULTS: The symptom relief rate was 95.9% for US-guided HIFU ablation and 89.1% for uterus-sparing surgery. The cumulative symptom recurrence rate at 1-, 3-, 5-, and 8 years was 1.7%, 6.8%, 9.4%, and 11.9% for US-guided HIFU ablation and 6.1%, 12.2%, 22.6%, and 27.8% for uterus-sparing surgery. Compared to uterus-sparing surgery group, US-guided HIFU ablation had a statistically higher symptom relief rate and a lower symptom recurrence rate (p < 0.05). The major complication rate was 3.1% in the uterus-sparing surgery group. No major complications occurred in the US-guided HIFU ablation group.
CONCLUSION: This study showed that the long-term clinical outcomes of US-guided HIFU ablation may be better that of uterus-sparing surgery for the treatment of symptomatic submucosal fibroids. US-guided HIFU ablation may also be safer than uterus-sparing surgery. Further larger randomized trials are needed to confirm these findings.